Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 12;10(1):e003497. doi: 10.1136/jitc-2021-003497

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The immune microenvironment is correlated with the response to neoadjuvant camrelizumab combined with chemotherapy. (A) Comparison of infiltrating CD4⁺ cells between the PCR group (n=5) and the non-PCR group (n=14) before and after treatment. (B) Comparison of infiltrating CD8⁺ cells between the PCR group (n=5) and the non-PCR group (n=14) before and after treatment. (C) Comparison of infiltrating PD-L1⁺ cells between the PCR group (n=5) and the non-PCR group (n=14) before and after treatment. (D) Comparison of infiltrating CD163⁺ cells between the PCR group (n=5) and the non-PCR group (n=14) before and after treatment. (E) Correlation between infiltrating PD-L1⁺ and CD163⁺ cells in post-treatment samples based on multiplex immunofluorescence staining (n=18). (F) Comparison of change in PD-L1⁺ CD163⁺ cells between the PCR group (n=5) and the non-PCR group (n=13) before and after treatment based on multiplex immunofluorescence staining. A significant increase in PD-L1⁺ CD163⁺ cells (white arrows) is observed after neoadjuvant chemoimmunotherapy in the non-PCR group. Antibody panel: CD8 (magenta), PD-1 (red), PD-L1 (green), CD163 (orange), cytokeratin (CK, yellow), and 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI, blue). (G) The percentage of patients with both TMB-H and PD-L1⁺ was significantly higher in the PCR group (n=5) than those in the non-PCR group (n=14). mIF, multiplex immunofluorescence; PCR, pathological complete response; PD-L1, programmed death-ligand 1; TMB-H, tumor mutation burden-high.